Revvity(US:RVTY) ZACKSยท2024-10-10 15:00Core Viewpoint - Revvity, Inc. has launched the EURORealTime APOE assay in European countries with CE mark approval, which is expected to enhance the company's position in the Alzheimer's disease treatment market by enabling accurate genotyping of the APOE gene [1][2]. Company Developments - The EURORealTime APOE PCR test allows for the simultaneous detection of the three most common APOE forms (E2, E3, E4) from a single blood sample, streamlining the genotyping process [3]. - The assay can be automated on Revvity's instruments, including the EUROIMMUN PreNAT II and chemagic 360 platforms, facilitating scalability in processing [3]. - Revvity's management is optimistic about the ongoing strong execution in its Diagnostics segment, which has shown slight revenue improvement in the second quarter of 2024 [7]. Industry Prospects - The global Alzheimer's therapeutics market was valued at $4.05 billion in 2022 and is projected to grow at a CAGR of approximately 19.9% from 2023 to 2030, driven by the rising prevalence of Alzheimer's disease and demand for effective treatments [6]. - The launch of the APOE assay is expected to significantly boost Revvity's business within this growing market [6]. Competitive Landscape - Eli Lilly's Kisunla (donanemab-azbt) received approval in Japan and the FDA for treating early symptomatic Alzheimer's, indicating strong competition in the Alzheimer's treatment space [8][9]. - Biogen, in collaboration with Eisai, has also made significant advancements with the approval of Leqembi for Alzheimer's treatment in Great Britain and the UAE, further intensifying competition [10][11]. - Intra-Cellular Therapies is actively enrolling patients in Phase 2 studies for treatments related to Alzheimer's, showcasing ongoing innovation in the industry [12][13].